Dan
Founder, Blueshot
Founder of Blueshot. Writes GLP-1 medication guides grounded in primary clinical sources (NEJM, JAMA, FDA labels) and real Korean/US pricing.
Articles
User StoriesTwo Years on a GLP-1: Does Staying on It Keep the Weight Off?
Past year one on semaglutide, I went looking for year two. STEP 5 tracked people to 104 weeks — the honest read on the average, the odds, and the catch.
NewsThe WHO Made Two Separate GLP-1 Calls in 2025
One headline said the WHO backed weight-loss drugs; another said it refused them. Both miss it: the agency made two separate 2025 calls.
LifestyleDo I Still Need Diet and Exercise on GLP-1s?
The shot quiets appetite — it doesn't pick your meals or lift your weights. Here's what the FDA and EMA labels actually say, and how to read STEP 1 honestly.
User StoriesI Stopped My GLP-1 and I'm Thinking About Restarting — Here's the Data
More than half quit a GLP-1 within a year, and many restart. What the real-world data says about stopping, weight regain, and going back at a lower dose.
Medication GuideFaster Heart Rate on a GLP-1: Expected, or a Red Flag?
A faster resting pulse on a GLP-1 is expected — semaglutide's label logs a 1-to-4-bpm rise. Here's how to tell that apart from a change worth a phone call.
Weight ManagementCan a GLP-1 Keep Prediabetes From Becoming Diabetes?
Over three years, tirzepatide sharply cut the slide from prediabetes to type 2 diabetes — but it's not an approved prevention drug, and the effect fades off it.
User StoriesDid Wegovy Break My Metabolism? What the Trials Found
I was scared the shot wrecked my metabolism and I'd gain it all back. Then I read what the trials measured on the drug. Here's what calmed me down.
Medication GuideStomach Bug or Flu on a GLP-1: When to Hold the Shot and How to Stay Hydrated
A stomach bug stacks on a gut your GLP-1 already slowed, and dehydration is the real risk. When to ask about pausing the dose, and the signs that mean call.
NewsYou Hit Your Goal Weight on a GLP-1 — Now What? Stay, Step Down, or Stop
Reaching your goal weight starts a separate decision: stay on, step down, or stop. Stop and the weight comes back; stay on and it holds. Here's the data behind each road.
User StoriesThree Months In and the Scale Won't Budge — Am I a Late Responder?
Twelve weeks on a GLP-1 and barely moved? In SURMOUNT-1, slow starters were 18% of people — and 90% of them still reached 5% by week 72. Here's the calm read.
Medication GuideMissed Your GLP-1 Shot? Take It or Skip It, by Drug, in 2026
Forgot your weekly injection? The answer depends on the drug. Wegovy, Ozempic, Mounjaro, Zepbound, and Saxenda each have their own window in the FDA label.
NewsTook Too Much GLP-1 by Accident? The Calm, Label-Based Plan for 2026
Accidentally double-dosed Ozempic or drew up too much tirzepatide from a vial? Here is the calm, label-based plan — what to do, what never to do, and when it is an emergency.
Weight ManagementMenopause Belly Fat and GLP-1s: What Wegovy Helps With, and What It Can't Touch
Midlife belly fat isn't a willpower problem — it's estrogen redistributing fat. A GLP-1 lowers weight, but it doesn't undo the hormone shift. Here's where the line sits.
LifestyleOn a GLP-1 and Tempted to Fast Harder? Read This First
The shot already quiets your appetite all week, so stacking a strict fast rarely speeds things up. Here's how to time meals, protect protein, and stay safe.
User StoriesOne Year on a GLP-1: The Honest Month-by-Month Shape of It
A first-person year on Wegovy or Ozempic — the queasy start, where the real loss lived, the plateau that wasn't failure, and why month twelve isn't a finish line.
NewsA Stronger Wegovy? What the 7.2 mg STEP UP Data Actually Says
Semaglutide 7.2 mg beat the approved 2.4 mg dose in STEP UP — 18.7% vs 15.6% weight loss. But the extra was 3.1 points, the gut effects rose, and 7.2 mg isn't approved yet.
Medication GuideTirzepatide vs. Semaglutide: What SURMOUNT-5 Settled (2026)
SURMOUNT-5 put both drugs in one trial: 20.2% vs. 13.7% weight loss at 72 weeks. The honest read on what that does — and doesn't — mean for you.
NewsCagriSema and the REDEFINE 1 Numbers: What 20.4% Actually Means
CagriSema posted 20.4% weight loss at 68 weeks in REDEFINE 1 — a large, well-controlled signal. Here's the honest read on the data, the GI tradeoff, and why it isn't here yet.
User StoriesWhat I Wish I Knew Before Starting a GLP-1 (Wegovy/Ozempic) in 2026
A first-person take on starting Wegovy or Ozempic — what the headline numbers leave out, how long the nausea really lasts, and why the data says it's a long road, not a quick fix.
Weight ManagementWeight Came Back After Bariatric Surgery? What the GLP-1 Trials Actually Show
Regain after sleeve or bypass is common, not failure. Two small post-surgery trials — BARI-OPTIMISE and BARI-STEP — show what adding a GLP-1 can do, and what it can't.
Medication GuideCould a Weight-Loss Shot Quiet Your Headaches? What Two Small Trials Found
Two early trials hint that GLP-1 drugs may lower brain pressure and cut headache days. Promising — but small, off-label, and not a headache drug yet.
NewsRetatrutide: The 24% Weight-Loss Headline, and Why You Still Can't Get It
Retatrutide hit a 24% mean weight loss at 48 weeks in a phase 2 trial — among the highest reported so far. Here's the triple-agonist mechanism, the real numbers, and why it's still not for sale.
Weight ManagementHow Fast Should You Lose Weight on a GLP-1? The Honest Math
The trials behind Wegovy and Zepbound ran 68 and 72 weeks. That alone tells you the real pace — and why chasing faster tends to backfire.
Medication GuideCan a GLP-1 Slow Parkinson's? Two Trials, Two Opposite Answers
One trial found lixisenatide slowed motor decline in early Parkinson's. A bigger, longer exenatide trial found nothing. Here's how to read two honest studies that disagree.
NewsWegovy and Heart Attacks: The SELECT Trial, No Diabetes
SELECT showed weekly semaglutide 2.4 mg cut major cardiovascular events 20% in people with obesity and heart disease but no diabetes. The honest read on a real but modest result.
Weight ManagementWegovy and HFpEF: What STEP-HFpEF Actually Showed
STEP-HFpEF tested semaglutide in people with obesity and HFpEF. Symptoms and walking improved, weight dropped. Here's what that does — and doesn't — prove.
Medication GuideWegovy for Teens: What STEP TEENS Showed Parents
In STEP TEENS, teens with obesity on semaglutide saw BMI fall 16.1% over 68 weeks vs +0.6% on placebo. Who it was for, and why it's a specialist call.
NewsOzempic and Leg Pain: What STRIDE Actually Showed About Walking Distance
STRIDE tested semaglutide in people with peripheral artery disease and type 2 diabetes. Walking distance rose about 13% over 52 weeks. Here's what that means — and doesn't.
LifestyleCan Ozempic Help You Quit Smoking? What the Trials Actually Show
People swear GLP-1 shots quiet cigarette cravings too. Three randomized trials weighed in — and the honest answer is more interesting than the hype.
Medication GuideDoes Wegovy Lower Your Blood Pressure? What the GLP-1 Data Says
GLP-1 shots like Wegovy and Zepbound nudge blood pressure down a few points — semaglutide by about 4.95 mmHg. Here's what that means, and the safety line.
Weight ManagementGLP-1 for PCOS: What Improves, and What's Still Off-Label
PCOS sits on insulin resistance and weight. GLP-1 drugs move both — but none is approved for PCOS. Here's what the trials show, and where the line is.
NewsA Weight-Loss Shot Eased Knee Arthritis Pain — Here's What STEP 9 Actually Showed
STEP 9 found semaglutide cut knee osteoarthritis pain far more than placebo — a WOMAC drop of 41.7 vs 27.5. What that means, and what it doesn't.
Medication GuideOn Mounjaro and the Pill? There's a 4-Week Rule You Probably Missed
Tirzepatide's label asks pill users to add backup birth control for 4 weeks after starting and after each dose increase. Here's why — and why semaglutide is different.
Weight ManagementGLP-1 and body composition: it's not the scale, it's where the fat goes
On semaglutide, visceral fat dropped 27.4% versus 19.3% for total fat. The scale tells you half the story — body composition tells the rest.
LifestyleOn GLP-1 and Never Thirsty? Here's Why You Keep Forgetting to Drink
GLP-1 medications dial down thirst along with appetite, so you sip less without noticing. Here's the science, the dehydration signs to watch, and how much to really drink.
NewsOzempic and Your Eyes: What the NAION Headlines Actually Mean in 2026
Ozempic blindness headlines miss the real story: two separate eye signals tied to semaglutide, and how small the actual risk is.
Weight ManagementWhen Dessert Stops Calling: How Sugar Cravings Change on GLP-1
Sugar stops calling on GLP-1 through two tracks: a quieter reward circuit and dulled sweet taste. What the trials show, and what to do when cravings creep back.
LifestyleGLP-1 and Sleep: Why Wegovy and Zepbound Mess With Your Rest — and How to Sleep Better in 2026
Some weeks on a GLP-1 you sleep like a rock; other weeks nausea wakes you at 3 a.m. Here's what's temporary, what lasts, and how to actually rest better.
Medication GuideWeight Regain After GLP-1: A Realistic Prevention Playbook
Two-thirds of the weight comes back within a year of stopping. The third who keep it off built specific habits while still on the drug. Here's how.
Medication GuideGLP-1 Constipation and Bloating: Why It Happens and What Actually Helps
Constipation hits about 24% on Wegovy and 12–17% on Zepbound/Mounjaro. A fiber-by-fiber, dose-by-dose guide to relief.
LifestyleThe GLP-1 wallet effect: how Wegovy and Zepbound are reshaping what Americans spend money on
From smaller grocery carts to bigger gym bills, millions of Americans on GLP-1s are quietly rerouting thousands of dollars a year. Here's where the money goes.
Weight ManagementGLP-1 and Eating Out: How to Handle Restaurants, Work Dinners, and Holiday Tables
Practical scripts, restaurant strategies, and a pre-dinner checklist for navigating social meals on Wegovy, Zepbound, and Foundayo — from office happy hours to Thanksgiving tables.
Medication GuideGLP-1 Fatigue: Why You're Exhausted and What Gets Your Energy Back
Fatigue hits 11-13% on Wegovy and Zepbound — but a caloric deficit, lost muscle mass, and dehydration make it worse. Here's what the data says and what you can do about it.
Medication GuideYour Brain on GLP-1: Why Food Noise Goes Silent
GLP-1 drugs rewire brain circuits that keep you thinking about food. The neuroscience of 'food noise,' why alcohol cravings fade too, and what happens when you stop.
Medication GuideGLP-1 Loose Skin: What's Real, What Helps, and When to Talk to a Surgeon
Lose 15-22% of your body weight on a GLP-1 and your skin can't keep up. What works for preventing loose skin — and what to do when it's already there.
Medication GuideVitamin Gaps on GLP-1s: Which Nutrients You're Probably Missing
Eating 40% less means absorbing 40% fewer vitamins. Vitamin D, B12, iron, calcium, and zinc are the biggest gaps on Wegovy, Mounjaro, and Ozempic — here's the testing and supplement plan.
Medication GuideGLP-1 Nausea, Bloating, and Sulfur Burps: What Helps and When to Worry
Nausea hits 44% on Wegovy and 33% on Mounjaro. Sulfur burps, constipation, and bloating follow close behind. A meal-by-meal, hour-by-hour playbook for the rough days.
Medication GuideGLP-1 Summer Travel Storage: Drug-by-Drug Cold Chain Guide (2026)
Car trunks hit 70°C in 30 minutes. Mounjaro's out-of-fridge window is just 21 days. Drug-by-drug packing plan for summer flights and road trips.
Medication GuideOzempic vs Wegovy: Same Drug, Different Rules
Ozempic and Wegovy are both semaglutide. Mounjaro and Zepbound are both tirzepatide. So why do they cost different amounts, and which one should you ask about?
Medication GuideSwitching GLP-1 Meds: Dose Maps and Real Talk
Thinking about switching from Wegovy to Mounjaro — or from injections to the new pill? Here's how dose mapping actually works and what the transition feels like.
Medication GuideGLP-1 and Bone Loss: What Rapid Weight Loss Does to Your Skeleton (2026)
Lose 15% of your body weight and you'll lose some bone too. DXA data from STEP and SURMOUNT show how much — and what actually protects you.
NewsGLP-1 Drugs Just Became the World's Best-Selling Drug Class (2026)
Novo Nordisk and Eli Lilly's GLP-1 revenue hit $60B+ annualized in Q1 2026, overtaking oncology. What record sales mean for pricing, supply, and access.
Medication GuideGLP-1 and Pancreatitis: Separating Real Risk from Internet Panic (2026)
Pancreatitis is on every GLP-1 label. Clinical trial rates are under 0.5%. Here's what STEP, SURMOUNT, and SELECT actually show.
Medication GuideGLP-1 and Thyroid Cancer: What the Black Box Warning Actually Means (2026)
Every GLP-1 drug carries a boxed warning about thyroid cancer. But 145,000-patient cohort data and 15 years of surveillance say the human risk is near zero. Here's the evidence.
Medication GuideGLP-1 and Gallbladder Problems: What the Data Actually Shows (2026)
Gallstones and cholecystitis are a real risk on semaglutide and tirzepatide — about 2–3% in trials vs 1% on placebo. Here's why it happens, who's most at risk, and what to watch for.
Medication GuideYour Stomach on a GLP-1: Gastroparesis, Nausea, and What the Evidence Actually Says
Gastroparesis fears, sulfur burps, nausea that makes you question everything — here's what the clinical data says about GLP-1s and your gut, and when to worry.
Medication GuideGLP-1 Long-Term Safety: What the Trial Data Shows (2026)
LEADER, SUSTAIN-6, REWIND, SELECT, SOUL, FLOW — 53,000+ patients, up to 5.4 years. What the long-term data says about thyroid, heart, kidneys, gallbladder, and more.
Medication GuideEvery Pill You Take With a GLP-1 — What Actually Interacts and What Doesn't
You're on Wegovy or Mounjaro and you take other meds too. Here's what the prescribing labels, clinical data, and your pharmacist actually worry about.
Medication GuideGLP-1 Weight Loss Plateau: Why You Stalled and What Actually Works
Most people hit a wall at months 3-6 on semaglutide or tirzepatide. The plateau isn't failure — it's biology. Here's what the STEP and SURMOUNT data says about breaking through.
Medication GuideYour Kidneys on GLP-1: What the FLOW Trial Found (and What It Means for You)
The FLOW trial stopped early because semaglutide cut major kidney events by 24%. If you have type 2 diabetes and CKD, here's what the 2024 data means for your kidneys.
NewsOral Semaglutide Hits 400K Users — Where the GLP-1 Pill Stands Globally
Four months after US launch, oral semaglutide for obesity has 400,000 patients on it. Here's which markets have it, which are next, and what the real-world data says so far.
NewsYour Liver Might Already Be Getting Better — GLP-1 and Fatty Liver Disease
If you're on a GLP-1 for weight loss, the ESSENCE and SYNERGY-NASH trials suggest your liver may be healing too. Here's what the 2024-2025 data actually shows.
NewsGLP-1 Failed the Alzheimer's Trial — But the Brain Story Isn't Over
Semaglutide failed the EVOKE+ Alzheimer's trial. Yet observational data still shows 40-70% lower dementia risk. Prevention and treatment are different questions.
Medication GuideYour Mood on GLP-1: What the Evidence Says About Depression, Anxiety, and 'Food Noise'
GLP-1 drugs changed how millions eat. Do they also change how you feel? Here's what clinical trials, brain science, and 2 million patient records actually show.
Medication GuideGLP-1 Drugs and Cancer Risk: What the 2026 Evidence Actually Shows
A 281,656-person study found GLP-1 users had 36% lower colorectal cancer risk than aspirin users. JAMA Oncology data adds 17% lower overall cancer risk across 14 types. Here's what the evidence means for you.
Medication GuideGLP-1 cost in 2026: insurance, cash price, and every path to coverage
Wegovy lists at $1,349. Zepbound at $1,059. Medicare covers both in July for $50. Every payment path — insurance, cash, coupons, and PA denial appeals.
Medication GuideGLP-1 Hair Loss in 2026: Why Month 4 Is the Shower-Drain Moment, and What Actually Helps
STEP 1 said 3.0%. SURMOUNT-1 said 5.7%. The mechanism is telogen effluvium, the timing is month 3 to 5, and the fix is not biotin gummies.
Medication GuideGLP-1 and Pregnancy in 2026: Washout Windows, the Pill Trap, and What OB-GYNs Now Say
Washout windows by molecule, the oral-contraceptive failure your prescriber probably didn't mention, and what regulators say in 2026.
Medication GuideGLP-1 and surgery: when to pause Wegovy, Zepbound, and Ozempic
When to hold Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, Trulicity, and Foundayo before anesthesia — exact pause windows, brand-by-market, and what to ask your team.
NewsCounterfeit Wegovy and Ozempic: How to Tell If Yours Is Real in 2026
Since 2023, the FDA, WHO, MHRA and a dozen national agencies have flagged fake Wegovy, Ozempic and Mounjaro. Here is how to verify the box in your hand.
Medication GuideWho qualifies for a GLP-1 in 2026: BMI, PA, and the Foundayo shift
The US gate is BMI 30 — or 27 with a comorbidity. Here's how that plays out at your PA, and why eight other countries draw the line elsewhere.
Medication GuideGLP-1 Protein Targets: How Many Grams You Actually Need in 2026
On Wegovy, Zepbound, Mounjaro, or Foundayo, 1.2–1.6 g/kg of protein daily is the number that separates fat loss from muscle loss. Here is how to hit it.
Medication GuideGLP-1 and Alcohol in 2026: Why One Drink Hits Like Four
Wegovy, Zepbound, Mounjaro, Ozempic plus a glass of wine — what the 2025 JAMA trial and real-world registry data actually say, and the practical guardrails nobody hands you.
Medication GuideGLP-1 Self-Injection at Home: The 2026 Pen Playbook
Wegovy, Zepbound, Mounjaro, Ozempic, Saxenda — how the weekly shot really goes, site by site, click by click, without wasting a $1,349 dose.
Weight ManagementGLP-1 Workout Plan: Lift, Walk, Keep the Muscle
A concrete weekly training plan for Wegovy, Zepbound, Mounjaro, Saxenda, and Foundayo users who want to lose fat without losing the strength underneath.
Weight ManagementOzempic face: why your cheeks deflate on Zepbound in 2026
Nine months into Zepbound, 42 lb down, and the mirror looks 10 years older. What the data says about Ozempic face — and the 6-month rule.
NewsZepbound for Sleep Apnea: The May 2026 Playbook
On July 1, 2026, Medicare opens Zepbound at $50/mo for SURMOUNT-OSA-qualifying beneficiaries. Here's what to do between now and then.
NewsThe US GLP-1 Rules Changed Again — What $39 Actually Buys You
March 2026: Novo and Hims restarted the deal at $39 for month one, $149 after. Here's what US shoppers actually get, and what it signals for everyone else.
User StoriesYour First Month on a GLP-1, Week by Week (2026)
Week one through week four on Wegovy or Zepbound — starting dose, the side-effect peak at day 3 to 5, food noise, and the month-one plateau that isn't one.
Medication GuideRybelsus and the SOUL Trial: An Oral GLP-1 Now Has a Heart Indication
SOUL is the first cardiovascular outcomes trial of an oral GLP-1. Rybelsus cut 3-point MACE 14% in T2D patients with established heart or kidney disease.
NewsMedicare's $50 Wegovy Lands July 1 — and Seoul, Tokyo and Dubai Feel It
July 1, 2026: 67 million Medicare enrollees get Wegovy and Zepbound for $50 a month. The ripple lands in Seoul, Tokyo, Berlin, Dubai and Taipei before Labor Day.
NewsGLP-1 and Addiction: What the March 2026 BMJ Study Actually Shows
A March 2026 BMJ study of 600,000+ US veterans ties GLP-1 drugs to lower new-onset addiction rates and fewer overdose deaths. Read it carefully.
Medication GuideMounjaro side effects in 2026: what's expected, what's a red flag
Nausea and reflux are common on tirzepatide. Sudden severe belly pain or a new neck lump are not. The SURMOUNT-1 numbers and what changed in 2026.
NewsThe Next Wave of Obesity Drugs: What's Actually Coming After Wegovy and Zepbound
CagriSema, retatrutide, amycretin, survodutide, MariTide — five late-stage obesity drugs and what each country's patients will see first as of April 2026.
Weight ManagementWhat to eat on Wegovy, Zepbound, and Foundayo in 2026
Protein target, nausea-safe foods, and a US grocery-aisle playbook for eating well on Wegovy, Zepbound, Mounjaro, Saxenda, and Foundayo.
Medication GuideSemaglutide vs. Tirzepatide in 2026: Same Two Molecules, Nine Different Pharmacies
Wegovy and Zepbound in the US. The same two molecules under different brand names in nine markets. SURMOUNT-5 put the head-to-head at −20.2% vs −13.7%.
Medication GuideHow much muscle are you losing on GLP-1? 2026 trial data
STEP 1 says about 40% of the weight lost on semaglutide is lean mass. SURMOUNT-1 says closer to 25%. Here is what that means.
Medication GuideMounjaro and Zepbound Dose Titration Schedule 2026
Tirzepatide climbs 2.5 mg to 15 mg on a fixed weekly ladder. The dose-by-dose Mounjaro and Zepbound schedule, and when holding beats pushing.
Medication GuideGeneric Saxenda in Korea: What the Liraglutide Copy Story Actually Means in 2026
The FDA cleared generic liraglutide in Dec 2024 and Biocon's gSaxenda in Feb 2026. Korea signed the deal — but 'approved' is not 'cheaper this month'.
Medication GuideStopping Wegovy or Zepbound: What the Trial Data Actually Shows About the Rebound
Hunger comes back in weeks. Weight comes back in months. The trial numbers on regain are less reassuring than most prescribers admit, so here is what the record shows.
Medication GuideMounjaro and Zepbound Cost in the US 2026: What You Really Pay
Tirzepatide is sold as two US brands — Mounjaro for type 2 diabetes, Zepbound for obesity. Here is what the April 2026 price lanes, PBM reality, and Lilly Self Pay vials add up to.
NewsAfter the GLP-1 crackdown: what U.S. patients do next
After the FDA cracked down on compounded semaglutide and tirzepatide, U.S. patients are making different choices about Wegovy, Zepbound, and the next refill.
Medication GuideWeight loss drugs 2026: which ones are actually approved in the U.S.?
If you search weight loss drugs 2026, the U.S. list looks bigger than it is. Here's the cleaner split between FDA-approved brands, what's sold, and what plans may cover.
Medication GuideAre Zepbound and Mounjaro the same drug? Same tirzepatide, different U.S. labels
Same tirzepatide, same dosing ladder. But in the U.S., Zepbound is the obesity brand and Mounjaro is the diabetes brand — and that changes coverage and cost.
Medication GuideWegovy side effects in 2026: what's normal, what's not
Nausea is common. Sudden severe belly pain or vision loss is not. What Wegovy side effects usually feel like, which are red flags, and what FDA/EMA changed.
Medication GuideWegovy Pill vs. Wegovy Shot in 2026: Cost, Dosing, Weight Loss, and Where Zepbound Fits
Oral Wegovy is a real daily tablet in the U.S. Different price ladder, dosing, and switching logic from the weekly shot. Clean 2026 comparison.
Medication GuideWegovy vs. Zepbound: Which One Makes More Sense in 2026?
US-first comparison of Wegovy and Zepbound: weight-loss data, side effects, coverage, cost, and the practical differences past the headline percentages.
NewsFoundayo in 2026: the new GLP-1 pill that skips fasting rules
Foundayo got FDA approval on April 1, 2026. A once-daily oral GLP-1 — no food or water restrictions. Here is what the label and ATTAIN trials actually say.
Medication GuideHow Much Wegovy Costs in Korea in 2026
In Korea, Wegovy has no single monthly price. The real number depends on dose, clinic fees, and treatment length. The cleanest way to budget in 2026.